Astellas Pharma Revenue 2012-2018 | ALPMY

Astellas Pharma annual/quarterly revenue history and growth rate from 2012 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Astellas Pharma revenue for the quarter ending June 30, 2018 was $3.028B, a 14.03% increase year-over-year.
  • Astellas Pharma revenue for the twelve months ending June 30, 2018 was $12.148B, a 6.62% increase year-over-year.
  • Astellas Pharma annual revenue for 2019 was $0B, a 100% decline from 2018.
  • Astellas Pharma annual revenue for 2018 was $12.267B, a 4.75% increase from 2017.
  • Astellas Pharma annual revenue for 2017 was $11.711B, a 2.79% increase from 2016.
Astellas Pharma Annual Revenue
(Millions of US $)
2019 $
2018 $12,267
2017 $11,711
2016 $11,393
2015 $11,350
2014 $11,067
2013 $10,698
2012 $11,822
2011 $11,791
2010 $10,519
2009 $9,947
2008 $9,395
2007 $7,650
2006 $7,993
Astellas Pharma Quarterly Revenue
(Millions of US $)
Q1 2018 $3,028
Q1 2017 $2,903
Q2 2016 $3,076
Q1 2016 $3,141
Q4 2016 $2,655
Q3 2015 $3,101
Q2 2015 $2,819
Q1 2015 $2,818
Q4 2015 $2,431
Q3 2014 $3,153
Q2 2014 $2,873
Q1 2014 $2,893
Q4 2014
Q3 2013
Q2 2013
Q1 2013 $2,786
Q4 2013
Q3 2012
Q2 2012
Q1 2012 $3,040
Q4 2012
Q3 2011
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $26.681B $11.834B
Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf applicable for the prevention of rejection in organ transplants, Vesicare for treatment of overactive bladder, Protopic for the treatment of atopic dermatitis in the topical immunomodulator class, Harnal to treat the functional symptoms of benign prostatic hyperplasia (BPH), including weak urinary stream, frequent nighttime urination, and sensation of incomplete emptying of the bladder and Fungard an antifungal agent. Astellas Pharma, Inc. is headquartered in Tokyo, Japan.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $59.871B 36.87
Takeda Pharmaceutical (TAK) Japan $26.123B 8.16
Grifols, S.A (GRFS) Spain $15.119B 19.29
UCB SA (UCBJF) Belgium $15.008B 0.00
Eisai (ESALY) Japan $14.535B 24.99
Merck (MKGAF) Germany $13.648B 18.62
Ionis Pharmaceuticals (IONS) United States $9.706B 20.93
Ono Pharmaceutical (OPHLF) Japan $9.383B 20.06
Neurocrine Biosciences (NBIX) United States $8.905B 0.00
IPSEN SA ADR (IPSEY) France $8.570B 0.00
Sage Therapeutics (SAGE) United States $8.368B 0.00
Catalent (CTLT) United States $8.137B 32.65
Jazz Pharmaceuticals (JAZZ) Ireland $7.634B 10.05
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $7.257B 19.83
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.781B 0.00
STADA ARZNEIMI (STDAF) Germany $5.547B 0.00
Orion OYJ (ORINY) Finland $5.275B 27.16
Hypermarcas (HYPMY) Brazil $4.913B 17.66
FibroGen (FGEN) United States $3.876B 96.96
United Therapeutics (UTHR) United States $3.568B 0.00
Nektar Therapeutics (NKTR) United States $3.172B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.143B 11.27
Evotec AG (EVTCY) Germany $3.127B 42.81
Tilray (TLRY) Canada $3.044B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $2.957B 67.80
PTC Therapeutics (PTCT) United States $2.660B 0.00
Xencor (XNCR) United States $2.306B 50.28
Zogenix (ZGNX) United States $2.111B 0.00
Portola Pharmaceuticals (PTLA) United States $2.078B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.591B 57.91
CLINIGEN GP (CLIGF) United Kingdom $1.577B 0.00
USANA Health Sciences (USNA) United States $1.500B 15.05
Corcept Therapeutics (CORT) United States $1.477B 20.30
Enanta Pharmaceuticals (ENTA) United States $1.416B 23.35
Ironwood Pharmaceuticals (IRWD) United States $1.372B 0.00
Heron Therapeutics (HRTX) United States $1.371B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.204B 0.00
ArQule (ARQL) United States $1.078B 0.00
Radius Health (RDUS) United States $1.066B 0.00
Aerie Pharmaceuticals (AERI) United States $1.065B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.904B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $0.724B 3.23
TherapeuticsMD (TXMD) United States $0.690B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.593B 0.00
Karyopharm Therapeutics (KPTI) United States $0.562B 0.00
Akebia Therapeutics (AKBA) United States $0.559B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.542B 0.00
Concordia (CXRXF) Canada $0.533B 0.00
Endo (ENDP) Ireland $0.512B 0.90
Indivior (INVVY) United States $0.487B 1.76
Aptorum Group (APM) China $0.472B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.453B 0.00
Dermira (DERM) United States $0.448B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.431B 19.58
ImmunoGen (IMGN) United States $0.424B 0.00
Siga Technologies (SIGA) United States $0.421B 0.98
Organogenesis Holdings (ORGO) United States $0.421B 0.00
Flexion Therapeutics (FLXN) United States $0.419B 0.00
Dova Pharmaceuticals (DOVA) United States $0.418B 0.00
Translate Bio (TBIO) United States $0.415B 0.00
ChemoCentryx (CCXI) United States $0.390B 0.00
Collegium Pharmaceutical (COLL) United States $0.386B 0.00
Innate Pharma SA (IPHYF) France $0.374B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.368B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.325B 0.00
CV Sciences (CVSI) United States $0.317B 0.00
Xeris Pharmaceuticals (XERS) United States $0.313B 0.00
CannTrust Holdings (CTST) Canada $0.297B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.286B 0.00
KalVista Pharmaceuticals (KALV) United States $0.285B 0.00
Harpoon Therapeutics (HARP) United States $0.283B 0.00
Lannett Co Inc (LCI) United States $0.266B 2.58
La Jolla Pharmaceutical (LJPC) United States $0.265B 0.00
OptiNose (OPTN) United States $0.263B 0.00
DURECT (DRRX) United States $0.261B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.252B 0.00
Concert Pharmaceuticals (CNCE) United States $0.249B 0.00
Recro Pharma (REPH) United States $0.242B 0.00
Calithera Biosciences (CALA) United States $0.216B 0.00
Ocular Therapeutix (OCUL) United States $0.211B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.189B 0.00
Molecular Templates (MTEM) United States $0.187B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.180B 0.00
Nature's Sunshine Products (NATR) United States $0.174B 29.03
Taiwan Liposome (TLC) Taiwan $0.165B 0.00
IMV INC (IMV) Canada $0.157B 0.00
Ardelyx (ARDX) United States $0.155B 0.00
Redhill Biopharma (RDHL) Israel $0.151B 0.00
GlycoMimetics (GLYC) United States $0.147B 0.00
Jounce Therapeutics (JNCE) United States $0.131B 0.00
Generex Biotechnology (GNBT) United States $0.128B 0.00
Majesco Entertainment (PTE) United States $0.121B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.117B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.112B 0.00
MEI Pharma (MEIP) United States $0.110B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.108B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.108B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.105B 0.00
Aquestive Therapeutics (AQST) United States $0.095B 0.00
Iterum Therapeutics (ITRM) Ireland $0.094B 0.00
Neos Therapeutics (NEOS) United States $0.092B 0.00
Mast Therapeutics (SVRA) United States $0.091B 0.00
Cardiome Pharma (CORV) Canada $0.089B 0.00
Nivalis Therapeutics (ALPN) United States $0.088B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.087B 33.11
Genocea Biosciences (GNCA) United States $0.082B 0.00
RENEURON GP (RNUGF) United Kingdom $0.080B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.077B 0.00
Natural Alternatives (NAII) United States $0.075B 7.54
MediWound (MDWD) Israel $0.074B 0.00
Champions Oncology (CSBR) United States $0.072B 618.00
China SXT Pharmaceuticals (SXTC) China $0.071B 0.00
Infinity Pharmaceuticals (INFI) United States $0.070B 0.00
Otonomy (OTIC) United States $0.069B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.066B 0.00
Capnia (SLNO) United States $0.064B 0.00
Novan (NOVN) United States $0.063B 0.00
SCYNEXIS (SCYX) United States $0.060B 0.00
Pharmaxis (PXSLY) Australia $0.060B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.059B 0.00
Lipocine (LPCN) United States $0.058B 0.00
Medicure (MCUJF) Canada $0.053B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.050B 0.00
ElectroCore (ECOR) United States $0.049B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.046B 0.00
Forward Pharma (FWP) Denmark $0.043B 0.00
CTI BioPharma (CTIC) United States $0.038B 0.00
Aclaris Therapeutics (ACRS) United States $0.036B 0.00
Mannatechorporated (MTEX) United States $0.035B 0.00
Bio-Path Holdings (BPTH) United States $0.035B 0.00
Melinta Therapeutics (MLNT) United States $0.032B 0.00
PharmAthene (ALT) United States $0.031B 0.00
Biomerica (BMRA) United States $0.031B 0.00
ProPhase Labs (PRPH) United States $0.023B 0.00
Opexa Therapeutics (ACER) United States $0.021B 0.00
Heat Biologics (HTBX) United States $0.019B 0.00
HANCOCK JAFFE (HJLI) United States $0.018B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.018B 1.41
Tetraphase Pharmaceuticals (TTPH) United States $0.016B 0.00
Achieve Life Sciences (ACHV) United States $0.015B 0.00
Cyanotech (CYAN) United States $0.014B 0.00
Shineco (TYHT) China $0.014B 0.00
Onconova Therapeutics (ONTX) United States $0.013B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.012B 0.00
Regulus Therapeutics (RGLS) United States $0.012B 0.00
VAXART, INC (VXRT) United States $0.010B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.009B 0.00
RXi Pharmaceuticals (PHIO) United States $0.009B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.008B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.006B 0.00
Jaguar Animal Health (JAGX) United States $0.006B 0.00
Flex Pharma (SLRX) United States $0.005B 0.00
Midatech Pharma (MTP) United Kingdom $0.004B 0.00
Xenetic Biosciences (XBIO) United States $0.002B 0.00
Advanced Accelerator Applications S.A (AAAP) France $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00